|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4166 | (2013.01) |
| A61K 31/196 | (2006.01) | ||
| A61K 31/69 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/196 | (2013.01) | ||
| A61K 9/48 | (2006.01) | ||
| A61K 31/192 | (2013.01) | ||
| A61K 31/195 | (2006.01) | ||
| A61K 31/277 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/58 | (2013.01) | ||
| A61K 31/192 | (2006.01) | ||
| A61K 31/4196 | (2013.01) | ||
| A61K 31/277 | (2006.01) | ||
| A61K 31/138 | (2013.01) | ||
| A61K 31/4166 | (2006.01) | ||
| A61K 31/5685 | (2013.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 31/4196 | (2006.01) | ||
| A61K 31/69 | (2013.01) | ||
| A61K 31/454 | (2006.01) | ||
| A61K 31/4545 | (2013.01) | ||
| A61K 31/4545 | (2006.01) | ||
| A61K 31/454 | (2013.01) | ||
| A61K 31/5685 | (2006.01) | ||
| A61K 31/58 | (2006.01) | ||
| A61K 31/138 | (2006.01) |
| (11) | Number of the document | 3380086 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16869301.8 |
| Date of filing the European patent application | 2016-11-23 | |
| (97) | Date of publication of the European application | 2018-10-03 |
| (45) | Date of publication and mention of the grant of the patent | 2021-10-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/063659 |
| Date | 2016-11-23 |
| (87) | Number | WO 2017/091762 |
| Date | 2017-06-01 |
| (30) | Number | Date | Country code |
| 201562260098 P | 2015-11-25 | US |
| (72) |
GHIAUR, Gabriel , US
JONES, Richard, J. , US
ALONSO, Salvador , US
CHANDRARATNA, Roshantha, A. , US
|
| (73) |
IO Therapeutics, Inc. ,
9450 Pinecroft Dr., Unit 9497, Spring, TX 77387,
US
The Johns Hopkins University , 3400 North Charles Street, Baltimore, MD 21218, US |
| (54) | CYP26-RESISTANT RAR-ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER |
| CYP26-RESISTANT RAR-ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER |